Regulatory function of parasites in autoimmune disease – outcome from experimental model infection

• Autorzy: Krawczak K. , Donskow-Lysoniewska K. , Doligalska M.
• Języki publikacji: EN

Abstrakty

EN

It is estimated that more than half of the nowadays known species are pathogenic parasites. Among macroparasites gastrointestinal nematodes are one of most common and having significant impact on life and health. Those organisms reveal strong, specific immune response in host, involving primary mechanisms associated with regulatory and Th2 cells. Referring to immunomodulatory abilities of helminths, parasite infections started to be considered as a possible therapy for many autoimmune diseases. Clinical trials on 2nd and 3rd stage are conducted in spite that treatment has not been recognized as safe for common use. Despite that the safety of treatment with parasites is still controversial and widely discussed. Our knowledge about mechanisms used by helminth to moderate immune response is still inadequate to predict possible effect of long lasting parasite infection on individual patients.

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2017
• Tom: 63
• Numer: 1
• Opis fizyczny: p.7-14,ref.

Twórcy

autor

Krawczak K.

• Department of Parasitology, Faculty of Biology, University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland

autor

Donskow-Lysoniewska K.

• Department of Parasitology, Faculty of Biology, University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland

autor

Doligalska M.

• Department of Parasitology, Faculty of Biology, University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland

Bibliografia

• [1] Brooks D.R., Hoberg E.P. 2006. Systematics and emerging infectious diseases: from management to solution. Journal of Parasitology 92: 426-429. doi:10.1645/ge-711r.1
• [2] Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., Bowman E.P. , Sgambellone N.M., Chan C.-C., Caspi R.R. 2008. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. Journal of Experimental Medicine 205: 799-810. doi:10.1084/jem.20071258
• [3] Benoist C., Mathis D. 2002. Mast cells in autoimmune disease. Nature 420: 875-878. doi:10.1038/nature01324
• [4] Whitacre C.C. 2001. Sex differences in autoimmune disease. Nature Immunology 2: 777-800.doi:10.1038 /ni0901-777
• [5] Rosati G. 2001. The prevalence of multiple sclerosis in the world: an update. Neurological Sciences 22: 117-139. doi:10.1007/s100720170011
• [6] Pugliatti M., Rosati G., Carton H., Riise T., Drulovic J., Vécsei L., Milanov I. 2006. The epidemiology of multiple sclerosis in Europe. European Journal of Neuro logy 13: 700-722. doi:10.1111/j.1468-1331.2006.01342.x
• [7] Charcot J.M. 1888. Clinical lectures on certain diseases of the nervous system. George S. Davis, Detroit, Michigan, USA.
• [8] Lassmann H. 2002. Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clinical Neuro logy and Neurosurgery 104: 168-171 http://dx.doi.org/10.1016/S0303-8467(02)00033-1
• [9] van Boxel-Dezaire A.H.H., Hoff S.C.J., van Oosten B.W., Verweij C.L., Dräger A.M., Adèr H.J., van Houwelingen J.C., Barkhof F., Polman C.H., Nagelkerken L. 1999. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Annals of Neurology 45: 695-703. doi:10.1002/1531-8249 (199906)45:6<695::AID-ANA3>3.0.CO;2-R
• [10] Cudrici C., Niculescu T., Niculescu F., Shin M.L., Rus H. 2006. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: protection of oligodendrocytes from apoptosis by complement. Journal of Rehabilitation Research and Development 43: 123-132. doi:10.1682/jrrd.2004.08.0111
• [11] Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., Benchimol E. I., Panaccione R., Ghosh S., Barkema H.W., Kaplan G.G. 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142: 46-54. http://dx.doi.org/10.1053/j.gastro.2011.10.001
• [12] Ardizzone S., Bianchi Porro G. 2005. Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286. doi:10.2165/00003495-200565160-00002
• [13] Khan W.I., Blennerhasset P.A., Varghese A.K., Chowdhury S.K., Omsted P., Deng Y., Collins S.M. 2002. Intestinal nematode infection ameliorates experimental colitis in mice. Infection and Immunity 70: 5931-5937. doi:10.1128/IAI.70.11.5931-5937.2002
• [14] Fuss I.J., Boirivant M., Lacy B., Strober W. 2002. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. Journal of Immunology 168: 900-908. doi:10.4049/jimmunol.168.2.900
• [15] Pol O., Puig M.M. 2004. Expression of opioid receptors during peripheral inflammation. Current Topics in Medicinal Chemistry 4: 51-61. doi:10 2174/1568026043451519
• [16] La Flamme A.C., Ruddenklau K., Bäckström B.T. 2003. Shistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infection and Immunity 71: 4996-5004. doi:10.1128/iai.71.9.4996-5004.2003
• [17] Rook G.A.W., Lowry C.A., Raison C.L. 2013. Microbial ”old friend”s, immunoregulation and stress resilience. Evolution, Medicine and Public Health 2013: 46-64. doi:10.1093/emph/eot004
• [18] Eizaguirre C., Lenz T.L., Kalbe M., Milinski M. 2012. Divergent selection on locally adapted major histocompatibility complex immune genes experimentally proven in the field. Ecology Letters 15: 723-731. doi:0.1111/j.1461-0248.2012.01791.x
• [19] Fumagalli M., Pozzoli U., Cagliani R., Comi G.P., Riva S., Clerici M., Bresolin N., Sironi M. 2009. Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions. Journal of Experimental Medicine 206: 1395-1408. doi:10.1084/jem.20082779
• [20] de Bellocq J.G., Charbonnel N., Morand S. 2008. Coevolutionary relationship between helminth diversity and MHC class II polymorphism in rodents. Journal of Evolutionary Biology 21: 1144-1150. doi:10.1111/j.1420-9101.2008.01538.x
• [21] Weinstock J.V., Elliott D.E. 2009. Helminths and the IBD hygiene hypothesis. Inflammatory Bowel Diseases 15: 128-133. doi:10.1002/ibd.20633
• [22] Correale J., Farez M. 2007. Association between parasite infection and immune responses in multiple sclerosis. Annals of Neurology 61: 97-108. doi:10.1002/ana.21067
• [23] Correale J., Farez M.F. 2011. The impact of parasite infections on the course of multiple sclerosis. Journal of Neuroimmunology 233: 6-11. http://dx.doi.org/10.1016/j.jneuroim.2011.01.002
• [24] Benzel F., Erdur H., Kohler S., Frentsch M., Thiel A., Harms L., Wandinger K.P., Rosche B. 2012. Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients. Journal of Helminthology 86: 339-347. https://doi.org/10.1017/s0022149x1100 0460
• [25] Monroy F.G., Enriquez F.J. 1992. Heligmosomoides polygyrus: a model for chronic gastrointestinal helminthiasis. Parasitology Today 8: 49-54. doi:10.1016/0169-4758(92)90084-f
• [26] Gause W.C., Urban J.F.Jr., Stadecker M.J. 2003. The immune response to parasitic helminths: insights from murine models. Trends in Immunology 24: 269-277. http://dx.doi.org/10.1016/s1471-4906(03)00101-7
• [27] Yazdanbakhsh M., van den Biggelaar A., Maizels R.M. 2001. Th2 responses without atopy: immuno-regulation in chronic helminth infections and reduced allergic disease. Trends in Immunology 22: 372-377. http://dx.doi.org/10.1016/s1471-4906(01)01958-5
• [28] Fairweather D., Cihakova D. 2009. Alternatively activated macrophages in infection and auto immunity. Journal of Autoimmunity 33: 222-230. http://dx.doi.org/10.1016/j.jaut.2009.09.012
• [29] Donskow-Łysoniewska K., Krawczak K., Doligalska M. 2012. Heligmosomoides polygyrus: EAE remission is correlated with different systemic cytokine profiles provoked by L4 and adult nematodes. Experimental Parasitology 132: 243-248. http://dx.doi.org/10.1016/j.exppara.2012.07.009
• [30] Elliott D.E., Setiawan T., Metwali A., Blum A., Urban J.F.Jr., Weinstock J.V. 2004. Heligmosomoides polygyrus inhibits established colitis in IL-10-deficient mice. European Journal of Immunology 34: 2690-2698. doi:10.1002/eji.200324833
• [31] Sewell D., Qing Z., Reinke E., Elliot D., Weinstock J., Sandor M., Fabry Z. 2003. Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization. International Immunology 15: 59-69. doi:10.1093/intimm/dxg012
• [32] van Liempt E., van Vliet S.J., Engering A., Vallejo J.J.G., Bank C.M.C., Sanchez-Hernandez M., van Kooyk Y., van Die I. 2007. Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. Molecular Immunology 44: 2605-2615. http://dx.doi.org/10.1016/j.molimm.2006.12.012
• [33] Tadokoro C.E., Vallochi A.L., Rios L.S., Martins G.A., Schlesinger D., Mosca T., Kuchroo V.K., Rizzo L.V., Abrahamsohn I.A. 2004. Experimental autoimmune encephalomyelitis can be prevented and cured by infection with Trypanosoma cruzi. Journal of Autoimmunity 23: 103-115. http://dx.doi.org/10.1016/j.jaut.2004.05.003
• [34] Gruden-Movsesijan A., Ilic N., Mostarica-Stojkovic M., Stosic-Grujicic S., Milic M., Sofronic-Milosavljevic Lj. 2008. Trichinella spiralis: modulation of experimental autoimmune encephalomyelitis in DA rats. Experimental Parasitology 118: 641-647. http://dx.doi.org/10.1016/j.exppara.2007.12.003
• [35] Wang A., Fernando M., Leung G., Phan V., Smyth D., McKay D.M. 2010. Exacerbation of oxazolone colitis by infection with the helminth Hymenolepis diminuta: involvement of IL-5 and eosinophils. American Journal of Pathology 177: 2850-2859. doi:10.2353/ajpath.2010.100537
• [36] Summers R.W., Elliott D.E., Qadir K., Urban J.F.Jr., Thompson R., Weinstock J.V. 2003. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. American Journal of Gastroenterology 98: 2034-2041. doi:10.1111/j.1572-0241.2003.07660.x
• [37] Summers R.W., Elliott D.E., Urban J.F.Jr., Thompson R.A., Weinstock J.V. 2005. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128: 825-832. doi:10.1053/j.gastro.2005.01.005
• [38] Rosche B., Werner J., Benzel F.J., Harms L., Danker-Hopfe H., Hellweg R. 2013. Serum levels of brain-derived neurotrophic factor (BNDF) in multiple sclerosis patients with Trichuris suis ova therapy. Parasite 20: 55. doi:10.1051/parasite/ 2013056
• [39] Pritchard D.I., Brown A. 2001. Is Necator americanus approaching a mutualistic symbiotic relationship with humans? Trends in Parasitology 17: 169-172. http://dx.doi.org/10.1016/S1471-4922(01) 01941-9
• [40] Croese J., O’Neil J., Masson J., Cooke S., Melrose W., Pritchard D., Speare R. 2006. A proof of concept study establishing Necator americanus in Crohn’s patients and reservoir donors. Gut 55: 136-137. doi:10.1136/gut.2005.079129
• [41] Feary J.R., Venn A.J., Mortimer K., Brown A.P., Hooi D., Falcone F.H., Pritchard D.I., Britton J.R. 2010. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clinical and Experimental Allergy 40: 299-306. doi:10.1111/j.1365-2222.20 09.03433.x
• [42] Harnett W., Frame M.J., Nor Z.M., Macdonald M., Houston K.M. 1994. Some preliminary data on the nature/structure of the PC-glycan of the major excretory-secretory product of Acantho cheilonema viteae (ES-62). Parasite 1: 179-181. http://dx.doi.org/10.1051/parasite/1994012179
• [43] Deehan M.R., Harnett M.M., Harnett W. 1997. A filarial nematode secreted product differentially modulates expression and activation of protein kinase C isoforms in B lymphocytes. Journal of Immunology 159: 6105-6111.
• [44] Al-Riyami L., Rodgers D.T., Rzepecka J., Pineda M.A., Suckling C.J., Harnett M.M., Harnett W. 2015. Protective effect of small molecule analogues of the Acanthocheilonema viteae secreted product ES-62 on oxazolone-induced ear inflammation. Experimental Parasitology 158: 18-22. http://dx.doi.org/10.1016/j.exppara.2015.03.025
• [45] Rzepecka J., Lucius R., Doligalska M., Beck S., Rausch S., Hartmann S. 2006. Screening for immunomodulatory proteins of the intestinal parasitic nematode Heligmosomoides polygyrus. Parasite Immu nology 28: 463-472. doi:10.1111/j.1365-3024.2006.00891.x
• [46] Doligalska M., Brodaczewska K., DonskowŁysoniewska K. 2012. The antiapoptotic activity of Heligmosomoides polygyrus antigen fractions. Parasite Immunology 34: 589-603. doi:10.1111/pim.12006
• [47] Zaccone P., Fehérvári Z., Jones F.M., Sidobre S., Kronenberg M., Dunne D.W., Cooke A. 2003. Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type 1 diabetes. European Journal of Immunology 33: 1439-1449. doi:10.1002/eji.200323910
• [48] Kuijk L.M., Klaver E.J., Kooij G., van der Pol S.M.A., Heijnen P., Bruijns S.C.M., Kringel H., Pinelli E., Kraal G., de Vries H.E., Dijkstra C.D., Bouma G., van Die I. 2012. Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation. Molecular Immunology 51: 210-218. http://dx.doi.org/10.1016/j.molimm.2012.03.020
• [49] Donskow-Schmelter K., Doligalska M., Rzepecka J., Jedlina-Panasiuk L. 2007. Heligmosomoides polygyrus: decreased apoptosis in fast responder FVB mice during infection. Experimental Parasitology 117: 149-156. http://dx.doi.org/10.1016/j.exppara.2007.04.001
• [50] Herrera L.A., Ostrosky-Wegman P. 2001. Do helminths play a role in carcinogenesis? Trends in Parasitology 17: 172-175. http://dx.doi.org/10.1016 /471-4922(00)01942-5

Identyfikatory

DOI

10.17420/ap6301.78